Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.
atezolizumab
bevacizumab
case series
combined hepatocellular-cholangiocarcinoma
immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
06
2023
accepted:
27
06
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.
Identifiants
pubmed: 37546425
doi: 10.3389/fonc.2023.1234113
pmc: PMC10401838
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1234113Informations de copyright
Copyright © 2023 Satake, Shibuki, Watanabe, Sasaki, Imaoka, Mitsunaga, Kojima and Ikeda.
Déclaration de conflit d'intérêts
MI has received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai, Chiome Bioscience, Delta-Fly Pharma, Eisai, Eli Lilly Japan, Invitae, MSD, J-Pharma, Merck Biopharma, Merus N.V., Novartis, Nihon Servier, Ono, Pfizer, and Syneos Health; has consulted for AstraZeneca, Chugai, MSD, Nihon Servier, and Novartis; and received speaker honoraria from AbbVie, AstraZeneca, Chugai, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Guardant Health Japan, Incyte Biosciences Japan, MSD, Nihon Servier, Novartis, Nippon Kayaku, Ono, Taisho Pharmaceutical, Teijin, Takeda, Taiho, and Yakult. SM has received research funding from Chugai, Astellas, Toray, Ajinomoto, and Pfizer; and received speaker honoraria from Ono, Toray, and Otsuka. HI has received research funding from Ono, and Novartis; has consulted for Nihon Servier; and received speaker honoraria from Yakult, AstraZeneca, Nihon Servier, Kaneka Medix, and SB-Kawasumi Laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Références
J Pathol. 2019 Jun;248(2):164-178
pubmed: 30690729
Liver Transpl. 2014 Aug;20(8):952-9
pubmed: 24777610
Hepatology. 2018 Jul;68(1):113-126
pubmed: 29360137
Clin Case Rep. 2022 Jul 25;10(7):e6129
pubmed: 35898742
Cancer Sci. 2018 Aug;109(8):2549-2557
pubmed: 29856900
Cancer. 2002 Apr 1;94(7):2040-6
pubmed: 11932907
Jpn J Clin Oncol. 2003 Jun;33(6):283-7
pubmed: 12913082
J Gastrointest Surg. 2006 Jul-Aug;10(7):987-98
pubmed: 16843869
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Hepatol Res. 2022 Jan;52(1):5-66
pubmed: 34050584
World J Gastroenterol. 2014 Sep 21;20(35):12615-20
pubmed: 25253966
Ann Surg Oncol. 2012 Sep;19(9):2869-76
pubmed: 22451237
J Gastroenterol. 2022 Nov;57(11):890-901
pubmed: 36161533
Am J Pathol. 1949 Jul;25(4):647-55
pubmed: 18152860
Cancer Cell. 2019 Jun 10;35(6):932-947.e8
pubmed: 31130341
World J Surg Oncol. 2019 Feb 27;17(1):43
pubmed: 30813932
Case Rep Oncol. 2020 Apr 30;13(1):478-484
pubmed: 32508620
Surg Today. 2006;36(10):892-7
pubmed: 16998683
Liver Int. 2021 Jun;41(6):1398-1408
pubmed: 33548073
Clin Cancer Res. 2022 Feb 1;28(3):540-551
pubmed: 34785581
Br J Cancer. 2018 Feb 6;118(3):325-330
pubmed: 29169182
Ann Surg Oncol. 2015 Dec;22(13):4130-7
pubmed: 26293835
J Clin Gastroenterol. 2011 Jan;45(1):69-75
pubmed: 20142755
J Surg Oncol. 2019 Mar;119(3):278-287
pubmed: 30554420
J Gastroenterol Hepatol. 2002 Apr;17(4):401-5
pubmed: 11982719
J Natl Compr Canc Netw. 2018 Oct;16(10):1193-1199
pubmed: 30323089